A comprehensive review of hormonal and biological therapies for endometriosis: latest developments

References

• Morotti M, Remorgida V, Venturini PL, et al. Endometriosis in menopause: a single institution experience. Arch Gynecol Obstet. 2012 Dec;286(6):1571–1575. PubMed PMID: 22825693.
   PubMed Web of Science ®Google Scholar
• Remorgida V, Ferrero S, Fulcheri E, et al. Bowel endometriosis: presentation, diagnosis, and treatment. Obstet Gynecol Surv. 2007 Jul;62(7):461–470. PubMed PMID: 17572918.
   PubMed Web of Science ®Google Scholar
• Leone Roberti Maggiore U, Ferrero S, Candiani M, et al. Bladder endometriosis: a systematic review of pathogenesis, diagnosis, treatment, impact on fertility, and risk of malignant transformation. Eur Urol. 2017 May;71(5):790–807. PubMed PMID: 28040358.
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Biscaldi E, et al. Ureteral endometriosis: a systematic review of epidemiology, pathogenesis, diagnosis, treatment, risk of malignant transformation and fertility. Hum Reprod Update. 2018;24:710–730. dmy027-dmy027.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Arena E, Morando A, et al. Prevalence of newly diagnosed endometriosis in women attending the general practitioner. Int J Gynaecol Obstet. 2010 Sep;110(3):203–207. PubMed PMID: 20546747.
   PubMed Web of Science ®Google Scholar
• Parazzini F, Esposito G, Tozzi L, et al. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol. 2016 Apr 30. PubMed PMID: 27216973. DOI:10.1016/j.ejogrb.2016.04.021
   Web of Science ®Google Scholar
• Vercellini P, Vigano P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014 May;10(5):261–275. PubMed PMID: 24366116.
   PubMed Web of Science ®Google Scholar
• Guerriero S, Condous G, Van den Bosch T, et al. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. Ultrasound Obstetrics Gynecol. 2016 Jun 28. PubMed PMID: 27349699. DOI:10.1002/uog.15955
   Web of Science ®Google Scholar
• Jacobson TZ, Duffy JM, Barlow D, et al. Laparoscopic surgery for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2009 (4):CD001300. PubMed PMID: 19821276. DOI:10.1002/14651858.CD001300.pub2
   PubMed Web of Science ®Google Scholar
• Shakiba K, Bena JF, McGill KM, et al. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol. 2008 Jun;111(6):1285–1292. PubMed PMID: 18515510.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Crosignani PG, Abbiati A, et al. The effect of surgery for symptomatic endometriosis: the other side of the story. Hum Reprod Update. 2009 Mar-Apr;15(2):177–188. PubMed PMID: 19136455.
   PubMed Web of Science ®Google Scholar
• Koga K, Takamura M, Fujii T, et al. Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Steril. 2015 Oct;104(4):793–801. PubMed PMID: 26354093.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Somigliana E, Consonni D, et al. Surgical versus medical treatment for endometriosis-associated severe deep dyspareunia: I. Effect on pain during intercourse and patient satisfaction. Hum Reprod. 2012 Dec;27(12):3450–3459. PubMed PMID: 22926841.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Somigliana E, Vigano P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs. 2009;69(6):649–675. PubMed PMID: 19405548.
   PubMed Web of Science ®Google Scholar
• Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2017 Jan 23;1:CD004753. PubMed PMID: 28114727.
   PubMedGoogle Scholar
• Menakaya U, Infante F, Condous G. Consensus on current management of endometriosis. Hum Reprod. 2013 Nov;28(11):3162–3163. PubMed PMID: 24014606.
   PubMed Web of Science ®Google Scholar
• Schweppe KW. Current place of progestins in the treatment of endometriosis-related complaints. Gynecol Endocrinol. 2001 Dec;15(Suppl 6):22–28. PubMed PMID: 12227883.
   PubMedGoogle Scholar
• Barra F, Scala C, Ferrero S. Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Expert Opin Drug Metab Toxicol. 2018 Apr 4. PubMed PMID: 29617576. DOI:10.1080/17425255.2018.1461840
   Web of Science ®Google Scholar
• Ferrero S, Alessandri F, Racca A, et al. Treatment of pain associated with deep endometriosis: alternatives and evidence [Review]. Fertil Steril. 2015;104(4):771–792.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Remorgida V, Venturini PL. Current pharmacotherapy for endometriosis. Expert Opin Pharmacother. 2010 May;11(7):1123–1134. PubMed PMID: 20230308.
   PubMed Web of Science ®Google Scholar
• Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999 Nov;181(5 Pt 1):1263–1269. PubMed PMID: 10561657.
   PubMed Web of Science ®Google Scholar
• Grandi G, Facchinetti F, Bitzer J. Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? Eur J Contracept Reprod Health Care. 2017 Aug;22(4):245–246. PubMed PMID: 28902531.
   PubMed Web of Science ®Google Scholar
• Grandi G, Cagnacci A, Fau - Volpe A, et al. Pharmacokinetic evaluation of desogestrel as a female contraceptive. (1744-7607 (Electronic)). eng.
   Google Scholar
• Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014 Mar;29(3):400–412. PubMed PMID: 24435778.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Buggio L, Berlanda N, et al. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016;106(7):1552–1571.e2.
   PubMed Web of Science ®Google Scholar
• Harada T, Kosaka S, Elliesen J, et al. Ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. Fertil Steril. 2017 Nov;108(5):798–805. PubMed PMID: 28911925.
   PubMed Web of Science ®Google Scholar
• Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008 Nov;90(5):1583–1588. PubMed PMID: 18164001.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Steril. 2018 Jul 1;110(1):137–152.e1. PubMed PMID: 29937152.
   PubMed Web of Science ®Google Scholar
• Vercellini P. Are combined hormonal contraceptives the neglected treatment for symptomatic endometriosis? Fertil Steril. 2018 Jul 1;110(1):61–62. PubMed PMID: 29908768.
   PubMed Web of Science ®Google Scholar
• Seracchioli R, Mabrouk M, Frasca C, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Steril. 2010 Jan;93(1):52–56. PubMed PMID: 18973896.
   PubMed Web of Science ®Google Scholar
• Muzii L, Maneschi F, Marana R, et al. Oral estroprogestins after laparoscopic surgery to excise endometriomas: continuous or cyclic administration? Results of a multicenter randomized study. J Minim Invasive Gynecol. 2011 Mar-Apr;18(2):173–178. PubMed PMID: 21262590.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010 May 1;93(7):2150–2161. PubMed PMID: 19328469.
   PubMed Web of Science ®Google Scholar
• Leone Roberti Maggiore U, Remorgida V, Scala C, et al. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand. 2014 Mar;93(3):239–247. PubMed PMID: 24372517.
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1–2):171–180. PubMed PMID: 19434889.
   PubMed Web of Science ®Google Scholar
• Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. Embo J. 1990 May;9(5):1603–1614. PubMed PMID: 2328727; PubMed Central PMCID: PMCPMC551856.
   PubMed Web of Science ®Google Scholar
• Grandi G, Mueller MD, Bersinger NA, et al. The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis. (1473-0766 (Electronic)). eng.
   Google Scholar
• Grandi G, Mueller M, Bersinger NA, et al. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. (1420-908X (Electronic)). eng.
   Google Scholar
• Grandi G, Mueller MD, Papadia A, et al. Inflammation influences steroid hormone receptors targeted by progestins in endometrial stromal cells from women with endometriosis. J Reprod Immunol. 2016 Sep;117:30–38. PubMed PMID: 27371899.
   PubMed Web of Science ®Google Scholar
• Grandi G, Mueller M, Bersinger N, et al. Progestin suppressed inflammation and cell viability of tumor necrosis factor-alpha-stimulated endometriotic stromal cells. Am J Reprod Immunol. 2016 Oct;76(4):292–298. PubMed PMID: 27515307.
   PubMed Web of Science ®Google Scholar
• Grandi G, Farulla A, Sileo FG, et al. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018 May;19(7):677–686. PubMed PMID: 29637798.
   PubMed Web of Science ®Google Scholar
• Maggiore ULR, Remorgida V, Scala C, et al. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand. 2014;93(3):239–247.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Remorgida V, Venturini PL, et al. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. Eur J Obstet Gynecol Reprod Biol. 2014 Mar;174:117–122. PubMed PMID: 24388845.
   PubMed Web of Science ®Google Scholar
• Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis–a pilot study. Contraception. 2009 Jan;79(1):29–34. PubMed PMID: 19041438; eng.
   PubMed Web of Science ®Google Scholar
• McKinnon B, Mueller M, Montgomery G. Progesterone resistance in endometriosis: an acquired property? Trends Endocrinol Metab. 2018 Aug;29(8):535–548. PubMed PMID: 29934050.
   PubMed Web of Science ®Google Scholar
• Barra F, Ferrero S. Adhesion proteins: suitable therapeutic targets or biomarkers of therapy response for endometriosis? Acta Obstet Gynecol Scand. 2019 Jan 16. PubMed PMID: 30648260. DOI:10.1111/aogs.13533
   PubMed Web of Science ®Google Scholar
• Abu Hashim H. Gonadotrophin-releasing hormone analogues and endometriosis: current strategies and new insights. Gynecol Endocrinol. 2012 Apr;28(4):314–321. PubMed PMID: 22303840.
   PubMed Web of Science ®Google Scholar
• Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010 (12):CD008475. PubMed PMID: 21154398.
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Bocciolone L, et al. Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study. Fertil Steril. 1993 Mar;59(3):516–521. PubMed PMID: 8458450.
   PubMed Web of Science ®Google Scholar
• Bergqvist A, Bergh T, Hogstrom L, et al. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Steril. 1998 Apr;69(4):702–708. PubMed PMID: 9548161.
   PubMed Web of Science ®Google Scholar
• Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron study group. Fertil Steril. 1990 Sep;54(3):419–427. PubMed PMID: 2118858.
   PubMed Web of Science ®Google Scholar
• Miller JD. Leuprolide acetate for the treatment of endometriosis. Prog Clin Biol Res. 1990;323:337–341. PubMed PMID: 2106145.
   PubMedGoogle Scholar
• Miller JD. Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. Am J Obstet Gynecol. 2000 Jun;182(6):1483–1488. PubMed PMID: 10871469.
   PubMed Web of Science ®Google Scholar
• Parazzini F, Di Cintio E, Chatenoud L, et al. Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Gruppo Italiano per lo Studio dell’Endometriosi. Eur J Obstet Gynecol Reprod Biol. 2000 Jan;88(1):11–14. PubMed PMID: 10659911.
   PubMed Web of Science ®Google Scholar
• Guzick DS, Huang LS, Broadman BA, et al. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril. 2011 Apr;95(5):1568–1573. PubMed PMID: 21300339; PubMed Central PMCID: PMCPMC4271794.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril. 1993 Jul;60(1):75–79. PubMed PMID: 8513962.
   PubMed Web of Science ®Google Scholar
• Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis–a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009 Mar;91(3):675–681. PubMed PMID: 18653184.
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010 Mar;25(3):633–641. PubMed PMID: 20089522.
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006 Feb;85(2):314–325. PubMed PMID: 16595206.
   PubMed Web of Science ®Google Scholar
• Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006 Jan;21(1):248–256. PubMed PMID: 16176939.
   PubMed Web of Science ®Google Scholar
• Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20(7):1993–1998.
   PubMed Web of Science ®Google Scholar
• Ferreira RA, Vieira CS, Rosa ESJC, et al. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception. 2010 Feb;81(2):117–122. PubMed PMID: 20103448.
   PubMed Web of Science ®Google Scholar
• Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011 Feb;95(2):492–496. PubMed PMID: 20883991.
   PubMed Web of Science ®Google Scholar
• Lemay A, Maheux R, Huot C, et al. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol. 1988 Feb;158(2):233–236. PubMed PMID: 3124618.
   PubMed Web of Science ®Google Scholar
• Dmowski WP, Radwanska E, Binor Z, et al. Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertil Steril. 1989 Mar;51(3):395–400. PubMed PMID: 2493400.
   PubMed Web of Science ®Google Scholar
• Dawood MY, Spellacy WN, Dmowski WP, et al. A comparison of the efficacy and safety of buserelin vs danazol in the treatment of endometriosis. Protocol 310 study group. Prog Clin Biol Res. 1990;323:253–267. PubMed PMID: 2106142.
   PubMedGoogle Scholar
• Agarwal SK, Hamrang C, Henzl MR, et al. Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin study group. J Reprod Med. 1997 Jul;42(7):413–423. PubMed PMID: 9252932.
   PubMed Web of Science ®Google Scholar
• Minaguchi H, Uemura T, Shirasu K. Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis–multicenter trial in Japan. Prog Clin Biol Res. 1986;225:211–225. PubMed PMID: 3097667.
   PubMedGoogle Scholar
• Henzl MR, Corson SL, Moghissi K, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med. 1988 Feb 25;318(8):485–489. PubMed PMID: 2963213.
   PubMed Web of Science ®Google Scholar
• Adamson GD, Kwei L, Edgren RA. Pain of endometriosis: effects of nafarelin and danazol therapy. Int J Fertil Menopausal Stud. 1994 Jul-Aug;39(4):215–217. PubMed PMID: 7951404.
   PubMedGoogle Scholar
• Hornstein MD, Yuzpe AA, Burry KA, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril. 1995 May;63(5):955–962. PubMed PMID: 7720940.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Remorgida V, Maganza C, et al. Aromatase and endometriosis: estrogens play a role. Ann N Y Acad Sci. 2014 May;1317:17–23. PubMed PMID: 24738993.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Gillott DJ, Venturini PL, et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review [Review]. Reprod Biol Endocrinol. 2011;9:89.
   Web of Science ®Google Scholar
• Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018 Jul 5. 1–17. PubMed PMID: 29975553. DOI: 10.1080/14656566.2018.1494154
   Web of Science ®Google Scholar
• Ferrero S, Biscaldi E, Luigi Venturini P, et al. Aromatase inhibitors in the treatment of bladder endometriosis. Gynecol Endocrinol. 2011 May;27(5):337–340. PubMed PMID: 20636231.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Venturini PL, Gillott DJ, et al. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reprod Biol Endocrinol. 2011;9:88. PubMed PMID: 21693037; PubMed Central PMCID: PMC3141645.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Camerini G, Ragni N, et al. Letrozole and norethisterone acetate in colorectal endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010 Jun;150(2):199–202. PubMed PMID: 20227163.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod. 2009 Dec;24(12):3033–3041. PubMed PMID: 19726448.
   PubMed Web of Science ®Google Scholar
• Remorgida V, Abbamonte HL, Ragni N, et al. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril. 2007 Sep;88(3):724–726. PubMed PMID: 17331508.
   PubMed Web of Science ®Google Scholar
• Remorgida V, Abbamonte LH, Ragni N, et al. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust N Z J Obstet Gynaecol. 2007 Jun;47(3):222–225. PubMed PMID: 17550490.
   PubMed Web of Science ®Google Scholar
• Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis [Article]. Hum Reprod. 2014;29(3):400–412.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Venturini PL, Ragni N, et al. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. Drugs. 2009 May 29;69(8):943–952. PubMed PMID: 19496625.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Leone Roberti Maggiore U, Scala C, et al. Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies [Article]. Arch Gynecol Obstet. 2013;287(3):447–453.
   PubMed Web of Science ®Google Scholar
• Seal SL, Kamilya G, Mukherji J, et al. Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review [Review]. Fertil Steril. 2011;95(1):291.e15-291.e18.
   Web of Science ®Google Scholar
• Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004 Jan;19(1):160–167. PubMed PMID: 14688176.
   PubMed Web of Science ®Google Scholar
• Alborzi S, Hamedi B, Omidvar A, et al. A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis [Article]. Arch Gynecol Obstet. 2011;284(1):105–110.
   PubMed Web of Science ®Google Scholar
• Hefler LA, Grimm C, Van Trotsenburg M, et al. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study [Article]. Fertil Steril. 2005;84(4):1033–1036.
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Mais V, et al. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs. 2018 Apr 30;27:445–458. PubMed PMID: 29708812.
   PubMed Web of Science ®Google Scholar
• Taniguchi F, Higaki H, Azuma Y, et al. Gonadotropin-releasing hormone analogues reduce the proliferation of endometrial stromal cells but not endometriotic cells. Gynecol Obstet Invest. 2013;75(1):9–15. PubMed PMID: 23147672.
   PubMed Web of Science ®Google Scholar
• Altintas D, Kokcu A, Tosun M, et al. Comparison of the effects of cetrorelix, a GnRH antagonist, and leuprolide, a GnRH agonist, on experimental endometriosis. J Obstet Gynaecol Res. 2008 Dec;34(6):1014–1019. PubMed PMID: 19012701.
   PubMed Web of Science ®Google Scholar
• Kupker W, Felberbaum RE, Krapp M, et al. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online. 2002 Jul-Aug;5(1):12–16. PubMed PMID: 12470539.
   PubMedGoogle Scholar
• Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009 Feb;94(2):545–551. PubMed PMID: 19033369; PubMed Central PMCID: PMCPMC2646513.
   PubMed Web of Science ®Google Scholar
• Struthers RS, Xie Q, Sullivan SK, et al. Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902. Endocrinology. 2007 Feb;148(2):857–867. PubMed PMID: 17095587.
   PubMed Web of Science ®Google Scholar
• Carr BG,L, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study. J Endometriosis. 2013;5(4):105–115.
   Google Scholar
• Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014 Nov;21(11):1341–1351. PubMed PMID: 25249568; PubMed Central PMCID: PMCPMC4212335.
   PubMed Web of Science ®Google Scholar
• Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014 Mar;21(3):363–371. PubMed PMID: 23885105.
   PubMed Web of Science ®Google Scholar
• Ács N, O’Brien C, Jiang P, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study. J Endometriosis. 2015;7(2):56–62.
   Google Scholar
• Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017 Jul 6;377(1):28–40. PubMed PMID: 28525302.
   PubMed Web of Science ®Google Scholar
• Food and Drugs Administration. Drug approval package: orilissa (elagolix sodium). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000TOC.cfm
   Google Scholar
• Ford MR, Turner MJ, Wood C, et al. Endometriosis developing during tamoxifen therapy. Am J Obstet Gynecol. 1988 May;158(5):1119. PubMed PMID: 3369493.
   PubMed Web of Science ®Google Scholar
• Le Bouedec G, Kauffmann P, Pingeon JM, et al. [Post-menopausal endometriosis developed during tamoxifen treatment]. Rev Fr Gynecol Obstet. 1991 May;86(5):407–410. PubMed PMID: 1871504.
   PubMedGoogle Scholar
• Yao Z, Shen X, Capodanno I, et al. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Invest Surg. 2005 Jul-Aug;18(4):177–183. PubMed PMID: 16126628.
   PubMed Web of Science ®Google Scholar
• Altintas D, Kokcu A, Kandemir B, et al. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010 May;150(1):84–87. PubMed PMID: 20188455.
   PubMed Web of Science ®Google Scholar
• Stratton P, Sinaii N, Segars J, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol. 2008 Jan;111(1):88–96. PubMed PMID: 18165396; PubMed Central PMCID: PMCPMC2755201.
   PubMed Web of Science ®Google Scholar
• Alvarez P, Bogen O, Levine JD. Role of nociceptor estrogen receptor GPR30 in a rat model of endometriosis pain. Pain. 2014 Dec;155(12):2680–2686. PubMed PMID: 25280432; PubMed Central PMCID: PMCPMC4250399.
   PubMed Web of Science ®Google Scholar
• Kulak J Jr., Fischer C, Komm B, et al. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology. 2011 Aug;152(8):3226–3232. PubMed PMID: 21586552; PubMed Central PMCID: PMCPMC3138238.
   PubMed Web of Science ®Google Scholar
• Sakr S, Naqvi H, Komm B, et al. Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment. Endocrinology. 2014 Apr;155(4):1489–1497. PubMed PMID: 24484171; PubMed Central PMCID: PMCPMC3959601.
   PubMed Web of Science ®Google Scholar
• Naqvi H, Sakr S, Presti T, et al. Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model. Biol Reprod. 2014 Jun;90(6):121. PubMed PMID: 24740602; PubMed Central PMCID: PMCPMC4093999.
   PubMed Web of Science ®Google Scholar
• Flores VA, Stachenfeld NS, Taylor HS. Bazedoxifene-conjugated estrogens for treating endometriosis. Obstet Gynecol. 2018 Aug;132(2):475–477. PubMed PMID: 29995747.
   PubMed Web of Science ®Google Scholar
• Hill AM, Lessey B, Flores VA, et al. Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis. Clin Case Rep. 2018 Jun;6(6):990–994. PubMed PMID: 29881549; PubMed Central PMCID: PMCPMC5986051.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Wada O, Takada I, et al. Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand. Biochem Biophys Res Commun. 2003 Dec 19;312(3):656–662. PubMed PMID: 14680815.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Shibata J, Yonekura K, et al. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res. 2005 Jan 1;11(1):315–322. PubMed PMID: 15671561.
   PubMed Web of Science ®Google Scholar
• Harada T, Ohta I, Endo Y, et al. SR-16234, a novel selective estrogen receptor modulator for pain symptoms with endometriosis: an open-label clinical trial. Yonago Acta Med. 2017 Dec;60(4):227–233. PubMed PMID: 29434492; PubMed Central PMCID: PMCPMC5803159.
   PubMed Web of Science ®Google Scholar
• Kettel LM, Murphy AA, Morales AJ, et al. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod. 1994 Jun;9(Suppl 1):116–120. PubMed PMID: 7962456.
   PubMed Web of Science ®Google Scholar
• Carbonell JL, Riveron AM, Leonard Y, et al. Mifepristone 2.5, 5, 10 mg versus placebo in the treatment of endometriosis. J Reprod Health Med. 2016;2(1):17–25.
   Google Scholar
• Xue HL, Yu N, Wang J, et al. Therapeutic effects of mifepristone combined with Gestrinone on patients with endometriosis. Pak J Med Sci. 2016 Sep-Oct;32(5):1268–1272. PubMed PMID: 27882034; PubMed Central PMCID: PMCPMC5103146.
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005 May;26(3):423–438. PubMed PMID: 15857972.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Vellone VG, Barra F, et al. Ulipristal acetate before hysteroscopic and laparoscopic surgery for uterine myomas: help or hindrance? Gynecol Obstet Invest. 2018 Dec 14:1–13. PubMed PMID: 30554215. DOI:10.1159/000495347
   PubMed Web of Science ®Google Scholar
• He W, Gauri M, Li T, et al. Current knowledge of the multifunctional 17beta-hydroxysteroid dehydrogenase type 1 (HSD17B1). Gene. 2016 Aug 15;588(1):54–61. PubMed PMID: 27102893.
   PubMed Web of Science ®Google Scholar
• Purohit A, Woo LW, Potter BV. Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism. Mol Cell Endocrinol. 2011 Jul 4;340(2):154–160. PubMed PMID: 21693170.
   PubMed Web of Science ®Google Scholar
• Thomas MP, Potter BV. Estrogen O-sulfamates and their analogues: clinical steroid sulfatase inhibitors with broad potential. J Steroid Biochem Mol Biol. 2015 Sep;153:160–169. PubMed PMID: 25843211.
   PubMed Web of Science ®Google Scholar
• Colette S, Defrere S, Van Kerk O, et al. Differential expression of steroidogenic enzymes according to endometriosis type. Fertil Steril. 2013 Dec;100(6):1642–1649. PubMed PMID: 24012197.
   PubMed Web of Science ®Google Scholar
• Colette S, Defrere S, Lousse JC, et al. Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model. Hum Reprod. 2011 Jun;26(6):1362–1370. PubMed PMID: 21441545.
   PubMed Web of Science ®Google Scholar
• Pohl O, Bestel E, Gotteland JP. Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256–1265. PubMed PMID: 24604234.
   PubMed Web of Science ®Google Scholar
• Delvoux B, D’Hooghe T, Kyama C, et al. Inhibition of type 1 17beta-hydroxysteroid dehydrogenase impairs the synthesis of 17beta-estradiol in endometriosis lesions. J Clin Endocrinol Metab. 2014 Jan;99(1):276–284. PubMed PMID: 24187399.
   PubMed Web of Science ®Google Scholar
• Maltais R, Trottier A, Roy J, et al. Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17beta-HSD1 for breast cancer and endometriosis treatments. J Steroid Biochem Mol Biol. 2018 Apr;178:167–176. PubMed PMID: 29248731.
   PubMed Web of Science ®Google Scholar
• Salah M, Abdelsamie AS, Frotscher M. First dual inhibitors of Steroid Sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): designed multiple ligands as novel potential therapeutics for estrogen-dependent diseases. J Med Chem. 2017 May 11;60(9):4086–4092. PubMed PMID: 28406629.
   PubMed Web of Science ®Google Scholar
• Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis [Article]. Hum Reprod Update. 2012;18(6):682–702.
   PubMed Web of Science ®Google Scholar
• Taylor RN, Yu J, Torres PB, et al. Mechanistic and therapeutic implications of angiogenesis in endometriosis [Conference Paper]. Reprod Sci. 2009;16(2):140–146.
   PubMed Web of Science ®Google Scholar
• Hey-Cunningham AJ, Peters KM, Zevallos HB, et al. Angiogenesis, lymphangiogenesis and neurogenesis in endometriosis. Front Biosci (Elite Ed). 2013 Jun;1(5):1033–1056. PubMed PMID: 23747918.
   Google Scholar
• Ricci AG, Olivares CN, Bilotas MA, et al. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis [Article]. Reprod Sci. 2011;18(7):614–622.
   PubMed Web of Science ®Google Scholar
• Soysal D, Klzlldaʇ S, Saatll B, et al. A novel angiogenesis inhibitor bevacizumab induces apoptosis in the rat endometriosis model [Article]. Balkan J Med Genet. 2014;17(2):73–80.
   PubMed Web of Science ®Google Scholar
• Kebapcilar AG, Ilhan TT, Dursunoglu D, et al. Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats. Gynecol Endocrinol. 2017 Dec;33(12):923–927. PubMed PMID: 28452240.
   PubMed Web of Science ®Google Scholar
• Moggio A, Pittatore G, Cassoni P, et al. Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis [Article]. Fertil Steril. 2012;98(6):1521–1530.e2.
   PubMed Web of Science ®Google Scholar
• Ozer H, Boztosun A, Açmaz G, et al. The efficacy of bevacizumab, Sorafenib, and retinoic acid on rat endometriosis model [Article]. Reprod Sci. 2013;20(1):26–32.
   PubMed Web of Science ®Google Scholar
• Yildiz C, Kacan T, Akkar OB, et al. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF agents, on the growth of experimental endometriosis in rats [Article]. Reprod Sci. 2015;22(11):1445–1451.
   PubMed Web of Science ®Google Scholar
• Pala HG, Erbas O, Pala EE, et al. The effects of sunitinib on endometriosis [Article]. J Obstetrics Gynaecol. 2015;35(2):183–187.
   PubMedGoogle Scholar
• Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor [Article]. Nat Med. 2002;8(2):128–135.
   PubMed Web of Science ®Google Scholar
• Laschke MW, Elitzsch A, Scheuer C, et al. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation [Article]. Br J Pharmacol. 2006;149(2):137–144.
   PubMed Web of Science ®Google Scholar
• Leconte M, Nicco C, Ngo C, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011 Aug;179(2):880–889. PubMed PMID: 21718677; PubMed Central PMCID: PMCPMC3157265.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015 Mar 10;33(8):930–936. PubMed PMID: 25624430; PubMed Central PMCID: PMCPMC4348638.
   PubMed Web of Science ®Google Scholar
• Allen C, Hopewell S, Prentice A, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2009 (2):CD004753. PubMed PMID: 19370608. DOI:10.1002/14651858.CD004753.pub3
   PubMed Web of Science ®Google Scholar
• Zhang RJ, Wild RA, Ojago JM. Effect of tumor necrosis factor-α on adhesion of human endometrial stromal cells to peritoneal mesothelial cells: an in vitro system [Article]. Fertil Steril. 1993;59(6):1196–1201.
   PubMed Web of Science ®Google Scholar
• Braun DP, Ding J, Dmowski WP. Peritoneal fluid-mediated enhancement of eutopic and ectopic endometrial cell proliferation is dependent on tumor necrosis factor-α in women with endometriosis [Conference Paper]. Fertil Steril. 2002;78(4):727–732.
   PubMed Web of Science ®Google Scholar
• D’Hooghe TM, Nugent NP, Cuneo S, et al. Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study [Article]. Biol Reprod. 2006;74(1):131–136.
   PubMed Web of Science ®Google Scholar
• Falconer H, Mwenda JM, Chai DC, et al. Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon [Article]. Hum Reprod. 2006;21(7):1856–1862.
   PubMed Web of Science ®Google Scholar
• Yildirim G, Attar R, Ficicioglu C, et al. Etanercept causes regression of endometriotic implants in a rat model [Article]. Arch Gynecol Obstet. 2011;283(6):1297–1302.
   PubMed Web of Science ®Google Scholar
• Islimye M, Kilic S, Zulfikaroglu E, et al. Regression of endometrial autografts in a rat model of endometriosis treated with etanercept [Article]. Eur J Obstet Gynecol Reprod Biol. 2011;159(1):184–189.
   PubMed Web of Science ®Google Scholar
• Zulfikaroglu E, Kilic S, Islimye M, et al. Efficacy of anti-tumor necrosis factor therapy on endometriosis in an experimental rat model [Article]. Arch Gynecol Obstet. 2011;283(4):799–804.
   PubMed Web of Science ®Google Scholar
• Cayci T, Akgul EO, Kurt YG, et al. The levels of nitric oxide and asymmetric dimethylarginine in the rat endometriosis modelj [Article]. J Obstetrics Gynaecol Res. 2011;37(8):1041–1047.
   PubMed Web of Science ®Google Scholar
• Koninckx PR, Craessaerts M, Timmerman D, et al. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod. 2008;23(9):2017–2023.
   PubMed Web of Science ®Google Scholar
• New L, Han J. The p38 MAP kinase pathway and its biological function [Review]. Trends Cardiovasc Med. 1998;8(5):220–228.
   PubMed Web of Science ®Google Scholar
• Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease [Review]. Mol Med Today. 1999;5(10):439–447.
   PubMedGoogle Scholar
• Yoshino O, Osuga Y, Hirota Y, et al. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis [Article]. Am J Reprod Immunol. 2004;52(5):306–311.
   PubMed Web of Science ®Google Scholar
• Seval Y, Cakmak H, Kayisli UA, et al. Estrogen-mediated regulation of p38 mitogen-activated protein kinase in human endometrium [Article]. J Clin Endocrinol Metab. 2006;91(6):2349–2357.
   PubMed Web of Science ®Google Scholar
• Yoshino O, Osuga Y, Hirota Y, et al. Endometrial stromal cells undergoing decidualization down-regulate their properties to produce proinflammatory cytokines in response to interleukin-1β via reduced p38 mitogen-activated protein kinase phosphorylation [Article]. J Clin Endocrinol Metab. 2003;88(5):2236–2241.
   PubMed Web of Science ®Google Scholar
• Zhou WD, Yang HM, Wang Q, et al. SB203580, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis by down-regulating proinflammatory cytokines and proteolytic factors in a mouse model [Article]. Hum Reprod. 2010;25(12):3110–3116.
   PubMed Web of Science ®Google Scholar
• Yoshino O, Osuga Y, Koga K, et al. FR 167653, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis in a murine model [Article]. J Reprod Immunol. 2006;72(1–2):85–93.
   PubMed Web of Science ®Google Scholar
• González-Ramos R, Van Langendonckt A, Defrre S, et al. Involvement of the nuclear factor-κB pathway in the pathogenesis of endometriosis [Review]. Fertil Steril. 2010;94(6):1985–1994.
   PubMed Web of Science ®Google Scholar
• Huber AV, Saleh L, Prast J, et al. Human chorionic gonadotrophin attenuates NF-κB activation and cytokine expression of endometriotic stromal cells [Article]. Mol Hum Reprod. 2007;13(8):595–604.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li M, Wang F, et al. Endometriotic epithelial cells induce MMPs expression in endometrial stromal cells via an NFB-dependent pathway [Article]. Gynecological Endocrinol. 2010;26(6):456–467.
   PubMed Web of Science ®Google Scholar
• Nasu K, Nishida M, Ueda T, et al. Application of the nuclear factor-κB inhibitor BAY 11-7085 for the treatment of endometriosis: an in vitro study [Article]. Am J Physiol Endocrinol Metab. 2007;293(1):E16–E23.
   PubMed Web of Science ®Google Scholar
• Lin M, Weng H, Wang X, et al. The role of tissue factor and protease-activated receptor 2 in endometriosis. Am J Reprod Immunol. 2012 Sep;68(3):251–257. PubMed PMID: 22672593.
   PubMed Web of Science ®Google Scholar
• Krikun G, Hu Z, Osteen K, et al. The immunoconjugate “icon” targets aberrantly expressed endothelial tissue factor causing regression of endometriosis [Article]. Am J Pathol. 2010;176(2):1050–1056.
   PubMed Web of Science ®Google Scholar
• Penning TM. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review. Expert Opin Ther Pat. 2017 Dec;27(12):1329–1340. PubMed PMID: 28895472; PubMed Central PMCID: PMCPMC5724044.
   PubMed Web of Science ®Google Scholar
• Beranic N, Lanisnik Rizner T. Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1–3):218–225. PubMed PMID: 23183084.
   PubMed Web of Science ®Google Scholar
• Hawkins SM, Creighton CJ, Han DY, et al. Functional microRNA involved in endometriosis. Mol Endocrinol. 2011 May;25(5):821–832. PubMed PMID: 21436257; PubMed Central PMCID: PMCPMC3082329.
   PubMedGoogle Scholar
• Adammek M, Greve B, Kassens N, et al. MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an in vitro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors. Fertil Steril. 2013 Apr;99(5):1346–1355 e5. PubMed PMID: 23312222.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen H, Fu Y, et al. MiR-195 inhibits proliferation and growth and induces apoptosis of endometrial stromal cells by targeting FKN. Int J Clin Exp Pathol. 2013;6(12):2824–2834. PubMed PMID: 24294368; PubMed Central PMCID: PMCPMC3843262.
   PubMed Web of Science ®Google Scholar
• Hirakawa T, Nasu K, Abe W, et al. miR-503, a microRNA epigenetically repressed in endometriosis, induces apoptosis and cell-cycle arrest and inhibits cell proliferation, angiogenesis, and contractility of human ovarian endometriotic stromal cells. Hum Reprod. 2016 Nov;31(11):2587–2597. PubMed PMID: 27619772.
   PubMed Web of Science ®Google Scholar
• Itoh F, Komohara Y, Takaishi K, et al. Possible involvement of signal transducer and activator of transcription-3 in cell-cell interactions of peritoneal macrophages and endometrial stromal cells in human endometriosis. Fertil Steril. 2013 May;99(6):1705–1713. PubMed PMID: 23461823.
   PubMed Web of Science ®Google Scholar
• Xu H, Zhang T, Man GC, et al. Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis. 2013 Jul;16(3):541–551. PubMed PMID: 23334337.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li D, Zhang Z, et al. Effect of siRNA against beta-NGF on nerve fibers of a rat model with endometriosis. Reprod Sci. 2014 Mar;21(3):329–339. PubMed PMID: 23885099.
   PubMed Web of Science ®Google Scholar
• Ma Y, He YL. Study of an antiangiogenesis gene therapy with endostatin on endometriosis in the nude mouse model. Clin Exp Obstet Gynecol. 2014;41(3):328–334. PubMed PMID: 24992787.
   PubMed Web of Science ®Google Scholar
• Koippallil Gopalakrishnan AR, Pandit H, Metkari SM, et al. Adenoviral vector encoding soluble Flt-1 engineered human endometrial mesenchymal stem cells effectively regress endometriotic lesions in NOD/SCID mice. Gene Ther. 2016 Jul;23(7):580–591. PubMed PMID: 26990775.
   PubMed Web of Science ®Google Scholar
• Gaytan M, Morales C, Bellido C, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and ovulation: lessons from morphology. Histol Histopathol. 2006 May;21(5):541–556. PubMed PMID: 16493584.
   PubMedGoogle Scholar
• Buggio L, Lazzari C, Monti E, et al. “Per vaginam” topical use of hormonal drugs in women with symptomatic deep endometriosis: a narrative literature review. Arch Gynecol Obstet. 2017 Sep;296(3):435–444. PubMed PMID: 28664485.
   PubMed Web of Science ®Google Scholar
• Barra F, Lorusso D, Leone Roberti Maggiore U, et al. Investigational drugs for the treatment of cervical cancer. Expert Opin Investig Drugs. 2017 Apr;26(4):389–402. PubMed PMID: 28274154; eng.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Ragni N, Remorgida V. Antiangiogenic therapies in endometriosis. Br J Pharmacol. 2006 Sep;149(2):133–135. PubMed PMID: 16894342; PubMed Central PMCID: PMCPMC2013795.
   PubMed Web of Science ®Google Scholar
• Barra F, Desideri Ferro L, Ferrero S. Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis. Br J Pharmacol. 2018 Sep;175(17):3626–3627. PubMed PMID: 29984446; PubMed Central PMCID: PMCPMC6086976.
   PubMed Web of Science ®Google Scholar
• Beedie SL, Mahony C, Walker HM, et al. Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model. Sci Rep. 2016 Jul 22;6:30038. PubMed PMID: 27443489; PubMed Central PMCID: PMCPMC4957076.
   PubMed Web of Science ®Google Scholar
• Barra F, Ferrero S. The use of retinoic acid for the treatment of endometriosis. Arch Gynecol Obstet. 2018;298:231–232. 2018/04/04.
   PubMed Web of Science ®Google Scholar
• Barra F, Ferrero S. Epigenetic drugs in the treatment of endometriosis. Reprod Sci. 2018 Jan 1:1933719118765987. PubMed PMID: 29575999. DOI:10.1177/1933719118765987
   Web of Science ®Google Scholar
• Barra F, Ferrero S. mTor inhibitors for the treatment of endometriosis. Geburtshilfe Frauenheilkd. 2018 Mar;78(3):283–284. PubMed PMID: 29576633; PubMed Central PMCID: PMCPMC5862551.
   PubMed Web of Science ®Google Scholar